Director of R&D Resource and Performance Management, Biogen
Daniel Rosan is a health care strategist & operator with 15 years of experience bringing innovative therapies to patients in the private & nonprofit sectors.
As head of Biogen’s R&D Resource & Performance Management team, Dan drives R&D capital expenditures, resource and portfolio planning, portfolio prioritization, and project management for Biogen’s industry leading portfolio of investigational neurology therapeutics. Dan recently drove the External Innovation component of Biogen’s Portfolio Transformation efforts. He has also served on the TYSABRI and SPINRAZA program teams, assessed multiple business development and M&A transactions, and advised on multi-billion dollar capital allocation decisions.
Prior to joining Biogen, Dan consulted with Frankel Group (acquired by Huron Consulting in 2014), a boutique firm serving biotechnology companies and investors. There he supported top-5 biopharmaceutical companies as well as top tier venture capital funds. He led the Interfaith Center on Corporate Responsibility’s health care practice for four years, with a focus on HIV/AIDS treatment access.
Dan has a BA in History from Vassar College and an MBA from Harvard Business School and serves on several not for profit Boards. He lives in Somerville, Massachusetts with his wife and two children.